We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Date
- 2024 (18)
- 2023 (45)
- 2022 (38)
- 2021 (36)
- 2020 (58)
- 2019 (31)
- 2018 (47)
- 2017 (11)
- 2016 (44)
- 2015 (37)
- 2014 (10)
- 2013 (12)
- 2012 (6)
- 2011 (6)
- 2010 (28)
- 2009 (4)
- 2008 (15)
- 2007 (1)
- 2006 (4)
- 2005 (11)
- 2004 (4)
- 2003 (5)
- 2002 (7)
- 2001 (5)
- 2000 (8)
- 1999 (2)
- 1998 (2)
- 1997 (4)
- 1996 (4)
- 1995 (4)
- 1993 (10)
- 1992 (3)
- 1991 (16)
Results for
"[search-keyword]"
Sponsor content
536 result(s) found, displaying 51 to 60
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd
-
Australian Public Assessment Report (AusPAR)AusPAR for Lucentis (ranibizumab) for the treatment of retinopathy of prematurity
-
Designation or determinationOrphan drug
-
Australian Public Assessment Report (AusPAR)AusPAR for JAKAVI (ruxolitinib phosphate) for the treatment of graft-versus-host disease.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SCEMBLIX asciminib (as hydrochloride) 20 mg film-coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SCEMBLIX asciminib (as hydrochloride) 40 mg film-coated tablet blister pack.
-
Australian Public Assessment Report (AusPAR)Scemblix (Asciminib) for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukaemia
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd